64 related articles for article (PubMed ID: 18454393)
1. [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?].
Tappeiner C; Perren B; Iliev ME; Frueh BE; Goldblum D
Klin Monbl Augenheilkd; 2008 May; 225(5):443-5. PubMed ID: 18454393
[TBL] [Abstract][Full Text] [Related]
2. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.
Jayaprakasam A; Ghazi-Nouri S
Orbit; 2010 Dec; 29(6):357-9. PubMed ID: 21158579
[TBL] [Abstract][Full Text] [Related]
3. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature.
Aydin S; Işikligil I; Tekşen YA; Kir E
Cutan Ocul Toxicol; 2010 Sep; 29(3):212-6. PubMed ID: 20670089
[TBL] [Abstract][Full Text] [Related]
4. Periorbital changes associated with topical bimatoprost.
Filippopoulos T; Paula JS; Torun N; Hatton MP; Pasquale LR; Grosskreutz CL
Ophthalmic Plast Reconstr Surg; 2008; 24(4):302-7. PubMed ID: 18645437
[TBL] [Abstract][Full Text] [Related]
5. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.
Park J; Cho HK; Moon JI
Jpn J Ophthalmol; 2011 Jan; 55(1):22-7. PubMed ID: 21331688
[TBL] [Abstract][Full Text] [Related]
6. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
Inoue K; Shiokawa M; Wakakura M; Tomita G
J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
[TBL] [Abstract][Full Text] [Related]
7. Periorbital changes associated with prostaglandin analogs in Korean patients.
Kim HW; Choi YJ; Lee KW; Lee MJ
BMC Ophthalmol; 2017 Jul; 17(1):126. PubMed ID: 28716077
[TBL] [Abstract][Full Text] [Related]
8. Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients.
Patradul C; Tantisevi V; Manassakorn A
Asia Pac J Ophthalmol (Phila); 2017; 6(3):238-242. PubMed ID: 28379653
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin-associated periorbitopathy.
Shrirao N; Khurana M; Mukherjee B
Indian J Ophthalmol; 2016 Jun; 64(6):459. PubMed ID: 27488155
[No Abstract] [Full Text] [Related]
10. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
[TBL] [Abstract][Full Text] [Related]
11. HIF2A-LOX Pathway Promotes Fibrotic Tissue Remodeling in Thyroid-Associated Orbitopathy.
Hikage F; Atkins S; Kahana A; Smith TJ; Chun TH
Endocrinology; 2019 Jan; 160(1):20-35. PubMed ID: 30388216
[TBL] [Abstract][Full Text] [Related]
12. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy.
Taketani Y; Yamagishi R; Fujishiro T; Igarashi M; Sakata R; Aihara M
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1269-76. PubMed ID: 24508785
[TBL] [Abstract][Full Text] [Related]
13. Challenging the "Topical Medications-First" Approach to Glaucoma: A Treatment Paradigm in Evolution.
Radcliffe NM; Shah M; Samuelson TW
Ophthalmol Ther; 2023 Dec; 12(6):2823-2839. PubMed ID: 37855977
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Two Different Trabecular MIGS Devices With and Without Ab Interno Canaloplasty in Patients with Primary Open-Angle Glaucoma.
Shultz M; Chorbajian A; Zohouralen A
Ophthalmol Ther; 2023 Dec; 12(6):3307-3322. PubMed ID: 37801274
[TBL] [Abstract][Full Text] [Related]
15. Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment.
Abalo-Lojo JM; Ferreiro PV; Asorey MK; Colmenero AE; Gonzalez F
Turk J Ophthalmol; 2023 Feb; 53(1):8-12. PubMed ID: 36847619
[TBL] [Abstract][Full Text] [Related]
16. Brimonidine Modulates the ROCK1 Signaling Effects on Adipogenic Differentiation in 2D and 3D 3T3-L1 Cells.
Umetsu A; Ida Y; Sato T; Watanabe M; Tsugeno Y; Furuhashi M; Hikage F; Ohguro H
Bioengineering (Basel); 2022 Jul; 9(7):. PubMed ID: 35877378
[TBL] [Abstract][Full Text] [Related]
17. Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells.
Ida Y; Hikage F; Umetsu A; Ida H; Ohguro H
Sci Rep; 2020 Sep; 10(1):16018. PubMed ID: 32994409
[TBL] [Abstract][Full Text] [Related]
18. Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists.
Chen JY; Le A; Caprioli J; Giaconi JA; Nouri-Mahdavi K; Law SK; Bonelli L; Coleman AL; Demer JL
Invest Ophthalmol Vis Sci; 2020 May; 61(5):46. PubMed ID: 32455434
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin F2α agonist-induced suppression of 3T3-L1 cell adipogenesis affects spatial formation of extra-cellular matrix.
Ida Y; Hikage F; Itoh K; Ida H; Ohguro H
Sci Rep; 2020 May; 10(1):7958. PubMed ID: 32409724
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
